Regarding research upon cytokine levels over time in the same group of psoriasis patients, Laura Mercurio et al. found that IL-38 (member of IL-1 family of cytokines, antagonist) might be a new biomarker to assess the treatment response of psoriasis patients treated with the anti-IL-17A drug, Secukinumab. Here, IL1F10 is linked to psoriasis.